HILDEN, Germany and GAITHERSBURG, Maryland, November 2, 2011 /PRNewswire/ --
- Vaginal Self-collection for Hybrid Capture®-based HPV Testing Increases Screening Coverage and is More Sensitive than Pap Smear Shows a Mexican Study Published Today Online in the Lancet
Promising findings published today online in the Lancet from a community-based, randomized equivalence trial undertaken by public health authorities in Mexico to investigate DNA home testing for human papillomavirus (HPV) compared with cytology (evaluation of cells) based on Pap smears. The study indicated that the relative sensitivity of HPV molecular testing was 3.4 times higher than cytology. Additionally, 4.2 times more invasive cancers were detected. The home testing study adds support to previous evidence that adding self-collection to the screening setup can increase the coverage rate of cervical cancer prevention programs, especially in underserved regions in developing and developed countries. The study was funded by the Instituto Nacional de Salud Pública (INSP), the Health Ministry of Mexico and QIAGEN.
"HPV testing is lower in cost, easier to implement, and has lower false-negative rates than cytology. Testing of self-collected vaginal samples offers increased coverage and acceptability," commented the lead study author, Dr. Eduardo Lazcano-Ponce, professor at the Centro de Investigación en Salud Poblacional of INSP in Morelos, Mexico.
The trial included 25,061 women of low socioeconomic status between 26 to 65 years from 540 rural communities in Morelos, Guerrero, and Mexico State, Mexico. They were randomly allocated to HPV DNA testing of a vaginal sample self-collected at home or cervical cytology at the nearest health center. Eight community nurses visited the self-collection women at home and instructed them how to use the digene® cervical sampler,
|SOURCE QIAGEN N.V.|
Copyright©2010 PR Newswire.
All rights reserved